Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations

v3.24.1
Consolidated Statements of Operations - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Income Statement [Abstract]    
Net Revenue $ 2,532,499 $ 4,803
Operating expenses:    
Direct costs and expenses 1,740,884 467
Research and development 1,467,936 1,378,624
Clinical development 256,661 145,546
Selling, general and administrative 6,790,654 2,481,042
Depreciation and amortization 249,592 10,182
Total operating expenses 10,505,727 4,015,861
Loss from operations (7,973,228) (4,011,058)
Other income (expense):    
Interest income 122,131 46,708
Interest expense (37,125) (2,532,640)
Other Income 3,325
Other Expense (31,121)
Gain on extinguishment of debt 212,258
Fair value adjustments on convertible notes payable (1,866,922)
Loss before income taxes (7,916,018) (8,151,654)
Income tax expense (20,993) (2,459)
Net loss $ (7,937,011) $ (8,154,113)
Net loss per common share, basic $ (0.91) $ (1.81)
Net loss per common share, diluted $ (0.91) $ (1.81)
Weighted average common shares outstanding, basic 8,747,509 4,498,964
Weighted average common shares outstanding, diluted 8,747,509 4,498,964